TheraTarget

3:30 PM - 3:45 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
TheraTarget holds the patent and licensing rights for a widely applicable polymer-anti-cancer agent delivery platform technology that dramatically improves the efficacy of traditional and novel anticancer agents by specifically targeting solid tumors, reducing adverse systemic effects, maximizing drug efficacy as well as creating an immunogeneic tumor microenvironment.
Our therapeutic targets are breast, non small cell lung cancer, pancreatic and ovarian cancers which total nearly 600,000 cases and over 250,000 deaths per year, respectively. These markets currently total $34B annually ($18B breast, $14B nsclc, $1.6B pancreatic and $1.4 B ovarian). Animal toxicology, IND submission and new patents for HPMA-epirubicin are our 2020 goals to achieve a PHARMA exit. Patent and licensing protection for the basic platform continues until 2031 with the opportunity for serial new patents available for combinations of new and off patent polymer-chemotherapeutic/-immunomodulating agents.
Company Type:
Company Website:
Company HQ State:
Utah
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
Biodegradable, HPMA [N-(2-hydroxypropyl) methacrylamide polymer platform for drug delivery
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One